Official UK procurement notice
Gene testing and reporting for Ovarian cancer specimens
Authority: NHS Greater Glasgow and Clyde (NHS & healthcare)
NHS Greater Glasgow and Clyde, Laboratory Genetics requires an end-to-end diagnostic service for FFPE block processing, DNA based Homologous Repair Deficiency (HRD) and BRCA1 and BRCA2 gene testing and reporting for Ovarian cancer specimens. This service is required for approximately 200 tests per annum and the service must be available by 1st December 2026. The technical processing and laboratory reporting must be validated to ISO 15189 (2022) standards or equivalent and the underlying technology used must be clinically validated with demonstrable assessment against clinical outcomes. The service must have a robust trackability process to ensure that FFPE blocks are processed sensitively and returned to Laboratory Genetics NHS GGC.
What is being bought
Published requirement descriptionNHS Greater Glasgow and Clyde, Laboratory Genetics requires an end-to-end diagnostic service for FFPE block processing, DNA based Homologous Repair Deficiency (HRD) and BRCA1 and BRCA2 gene testing and reporting for Ovarian cancer specimens. This service is required for approximately 200 tests per annum and the service must be available by 1st December 2026.
CPV: Services provided by medical laboratories
Open work like this
This notice no longer takes bids · live search, filters set
The lotProcurement structure
single lot · no lot value publishedLot #1NHS Greater Glasgow and Clyde requires an end-to-end diagnostic service for FFPE block…
NHS Greater Glasgow and Clyde requires an end-to-end diagnostic service for FFPE block processing, DNA based Homologous Repair Deficiency (HRD) and BRCA1 and BRCA2 gene testing and reporting for Ovarian cancer specimens. The technical processing and laboratory reporting must be validated to ISO 15189 (2022) standards or equivalent and the underlying technology used must be clinically validated with demonstrable assessment against clinical outcomes.
The service must have a robust trackability process to ensure that FFPE blocks are processed sensitively and returned to Laboratory Genetics NHS GGC.
This service is required for approximately 200 tests per annum and the service must be available by 1st December 2026.
The provider must be able to meet NHS GGC boards Information Technology and Security and Information Governance frameworks by completion of Data Protection Impact Assessment (DPIA), and establishing a Data Processing Agreement (DPA) along with a Systems Security Policy (SSP) as applicable. All information governance, cyber-security and any contractual agreements must be established and in place by 01/12/2026 as the current HRD service, based within the UK, will cease to exist from 01/12/2026.
The supplier must be able to provide a fixed cost per test, between 01/12/2026-31/12/2027.
There are no Scottish Genomic Laboratories able to provide this test. We require a rapid solution to ensure that patients needing the HRD test can access the test and associated treatment pathways based on the test result. Not having a test available for this patient cohort will lead to significant patient harm and even early death. Additional information: Contract valid 01/12/2026 - 31/12/2027
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Myriad Genetics | £363,000 † | — | Awarded |
Contracts
Contract 109560-2026-1 · Myriad Genetics
- Signed
- 12 Nov 2026
- Value
- £363,000
- Status
- active
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Award procedure without prior publication of a call for competition
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Services
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 19 Nov 2026, 09:39 GMT
- Last source update
- 19 Nov 2026, 09:39 GMT
- FTS notice number
2026/S 000-109560- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-07bf2eFind a Tender
- Why no open competition
- The procurement falls outside the scope of application of the directive
- Published justification
NHSGGC will follow Regulation 33, (c)where (but only if it is strictly necessary) for reasons of extreme urgency brought about by events unforeseeable by the contracting authority, the time limits for open procedure, restricted procedure or competitive procedure with negotiation cannot be complied with.
NHS GGC were informed on 03/11/2026 that the current HRD service, based within the UK, will no longer be available beyond 01/12/2026.
NHS GGC require a rapid solution as this highly-specialist test cannot cease, to ensure that patients needing the HRD test can access the test and associated treatment pathways based on the test result.
Publisher note: NOTE: To register your interest in this notice and obtain any additional information please visit the Public Contracts Scotland Web Site at https://www.publiccontractsscotland.gov.uk/Search/Search_Switch.aspx?ID=848772. (SC Ref:848772)
Contracting authority & participating public bodies
Dispute resolution & review bodies
- Glasgow Sheriff CourtReview body
Bidders & participating suppliers
1 commercial party on the notice- Myriad GeneticsAwarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.